Try our Advanced Search for more refined results
Life Sciences
-
December 05, 2025
Medline Accused In Chancery Of Withholding $10M Earnout
A Florida-based holding company and its founder have sued medical supplier Medline in the Delaware Chancery Court, alleging it deliberately refused to make a $10 million payment tied to a 2023 acquisition, missed a hard deadline and is now acting in bad faith to avoid paying the key portion of the sale price.
-
December 05, 2025
Mass Tort Firms Targeted Over Benicar MDL Fees In NJ Suits
Robins Kaplan LLP and Pendley Baudin & Coffin were hit with proposed class actions in New Jersey state court from former clients in multidistrict litigation over the blood pressure medication Benicar alleging that the firms overcharged on their fees.
-
December 05, 2025
CDC Panel Ends Recommendation Of Hepatitis B Shot At Birth
A panel of federal vaccine advisers on Friday voted to lift a long-standing recommendation that all newborns be given vaccinations for hepatitis B.
-
December 04, 2025
Wheeling & Appealing: The Latest Must-Know Appellate Action
Is the False Claims Act constitutional? Will Mark Zuckerberg be deposed in high-profile privacy litigation? Did a major drugmaker's shenanigans cost investors nearly $7 billion? That's a small sample of the intriguing legal questions we're exploring in this preview of December's top appellate action.
-
December 04, 2025
Class Cert. Denied In Splenda False Ad Suit
A California federal judge on Wednesday declined to certify a class of consumers who claim that Splenda falsely advertised that its sweetener packets were "suitable for people with diabetes," partly because the lead plaintiff is prediabetic.
-
December 04, 2025
11th Circ. Blocks Fla. City's Abortion Clinic Buffer Zone Law
The Eleventh Circuit on Thursday ordered a preliminary injunction blocking a Clearwater, Florida, ordinance requiring a 5-foot buffer zone outside an abortion clinic, finding the city likely violated protesters' rights by burdening their ability to leaflet drivers.
-
December 04, 2025
Squires Clarifies Points On Patent Eligibility Declarations
U.S. Patent and Trademark Office Director John Squires is reminding applicants that they can file declarations explaining why their patents are eligible under Section 101 of the Patent Act and that examiners need to consider them when filed.
-
December 04, 2025
CDC Vaccine Committee Punts Hepatitis B Vote Again
Federal vaccine advisers on Thursday put off a vote on changing guidelines for a long-used hepatitis B vaccine for infants, delaying again a decision expected to have wide-ranging ramifications for national childhood vaccine policy in the U.S.
-
December 04, 2025
Fla. High Court Backs University Control Over Nonprofit
The Florida Supreme Court on Thursday ruled that a university can control a research nonprofit's budget and approve its board members, saying a state law doesn't impair a memorandum of understanding between the two parties.
-
December 04, 2025
Geico Claims Cos. Ran $2.7M Medical Device Billing Scheme
Two New York companies exploited the state's no-fault insurance laws by fraudulently billing Geico more than $2.7 million for unnecessary durable medical equipment for drivers involved in auto accidents who could receive no-fault coverage, the insurer told a New York federal court Thursday.
-
December 04, 2025
Medical Device Co. Faces Investor Suit Over IV Pump Issues
Medical device company Baxter International Inc. has been hit with a proposed investor class action accusing it of falsely claiming that it resolved issues associated with an IV pump before recalling the product this year.
-
December 04, 2025
Pharma Cos. Denied Early Win In States' Price-Fixing Suit
Twenty-six pharmaceutical companies failed to secure a quick win on overarching conspiracy claims in an antitrust case by the attorneys general of Connecticut and most other states, with a federal judge finding the "substantial bulk of evidence" points toward a broad industry scheme to fix 98 dermatology drug prices.
-
December 04, 2025
Judge Nixes Hagens Berman's Recusal Bid After DOJ Referral
Two days after referring powerhouse plaintiffs firm Hagens Berman to the U.S. Department of Justice for alleged misconduct, a Pennsylvania federal judge on Thursday dismissed the firm's request that he recuse himself from the long-running product liability suit, calling the firm's arguments "absurd."
-
December 04, 2025
Vivimed To Pay $1.9M To End Losartan Economic Loss Claims
Vivimed has agreed to pay $1.9 million to settle economic loss claims from a class of consumers and insurers related to its losartan product in sprawling multidistrict litigation over contaminated blood pressure medication, according to a Wednesday filing.
-
December 03, 2025
USPTO Gets Earful On Plan To Restrict Patent Reviews
The U.S. Patent and Trademark Office's proposed new rules to limit America Invents Act patent reviews have generated scores of forceful comments, with supporters saying the proposal will curb redundant challenges and opponents arguing it would bar legitimate reviews and exceed the office's power.
-
December 03, 2025
Pharmacies Want Opioid Mistrial As Deliberations Stretch On
The nation's three major pharmacy chains asked a Florida state judge Wednesday to declare a mistrial following 11 days of deliberations in a $1.5 billion case by hospitals over opioid dispensing, claiming jurors seem unaware that they are allowed to report a deadlock.
-
December 03, 2025
Pharma Co. Exec Faces $125K SEC Judgment In Fraud Case
A New York federal judge on Wednesday approved a $125,000 civil penalty against the former chief science officer of BioZone Pharmaceuticals Inc. for his alleged involvement in a purported pump-and-dump scheme involving the company's stock.
-
December 03, 2025
NuVasive Urges Del. Justices To Revive Officer Conflict Suit
A Delaware vice chancellor applied the wrong standards in tossing a suit alleging a former officer of spine surgery tech venture NuVasive Inc. ran an insider scheme to lure surgeons to a competitor while planning his own jump, an attorney for NuVasive told a Delaware Supreme Court panel on Wednesday.
-
December 03, 2025
Kevin O'Leary, Company Execs Fight Patent Forgery Suit
A livestock technology company and several of its executives and investors, including Kevin O'Leary of "Shark Tank," have asked a Colorado federal judge to throw out the lawsuit against them by the company's founder, who claims the defendants stole her company and intellectual property.
-
December 03, 2025
'Dr. P.' Gets 2.5 Years For Selling Ketamine To Matthew Perry
A California federal judge sentenced a former physician who supplied Matthew Perry with ketamine before the "Friends" actor's overdose death to 2 years and 6 months in prison Wednesday, following the doctor's July guilty plea to four counts of illegally distributing the drug.
-
December 03, 2025
AT&T Sues Generic Drug Manufacturers, Alleging Price-Fixing
AT&T has joined the bevy of litigants suing a swath of pharmaceutical companies over alleged generic drug price-fixing, claiming it shelled out billions of dollars for medication reimbursements to the drugmakers as part of its employee health plans when it could have spent far less if the drugs weren't subject to anticompetitive pricing.
-
December 03, 2025
Novartis, Swiss Marketer Want Out Of Trade Secrets Suit
A Swiss marketing company and its founder have joined pharmaceutical giant Novartis in asking a Manhattan federal judge to release them from a hedge fund's suit accusing the founder of brokering business meetings with Novartis in a scheme to steal its strategy, claiming the suit is merely an attempt to punish Novartis for placing money with a competitor.
-
December 03, 2025
Fed. Circ. Backs Axed Claims In Heart Rate Monitor Patent
The Federal Circuit on Wednesday upheld a Utah federal court's decision that claims in a wireless heart rate monitor patent owned by Finnish sports tech company Polar Electro Oy were invalid under the U.S. Supreme Court's Alice test.
-
December 03, 2025
Judge To OK $16.5M 23andMe Insurer Buyback Deal In Ch. 11
A Missouri bankruptcy judge Wednesday agreed to approve a $16.5 million settlement between genetic testing company 23andMe and its insurers, in which the carriers proposed to buy back the unused portion of their cyber coverage.
-
December 03, 2025
AGs Say Sun, Taro Settlement Mustn't Touch State Claims
State attorneys general have asked a Pennsylvania federal judge to again ensure their claims remain untouched by a settlement between private plaintiffs and generic-drug makers in sprawling price-fixing litigation, this time focusing on a $200 million deal between Sun Pharmaceutical, Taro Pharmaceuticals and employee benefit plans.
Expert Analysis
-
9th Circ. Ruling May Help Pharma Cos. Avert Investor Claims
The Ninth Circuit's recent decision affirming the dismissal of a securities fraud class action alleging that Talphera deceived investors by marketing a drug with a misleading slogan should give plaintiffs pause before filing similar complaints where snappy slogans are accompanied by copious clarifying information, say attorneys at Simpson Thacher.
-
What Ethics Rules Say On Atty Discipline For Online Speech
Though law firms are free to discipline employees for their online commentary about Charlie Kirk or other social media activity, saying crude or insensitive things on the internet generally doesn’t subject attorneys to professional discipline under the Model Rules of Professional Conduct, says Stacie H. Rosenzweig at Halling & Cayo.
-
Junior Attys Must Beware Of 5 Common Legal Brief Mistakes
Excerpt from Practical Guidance
Junior law firm associates must be careful to avoid five common pitfalls when drafting legal briefs — from including every possible argument to not developing a theme — to build the reputation of a sought-after litigator, says James Argionis at Cozen O'Connor.
-
Opinion
State AGs, Not Local Officials, Should Lead Public Litigation
Local governments’ public nuisance lawsuits can raise constitutional and jurisdictional challenges, reinforcing the principle that state attorneys general — not municipalities — are best positioned to litigate on behalf of citizens when it is warranted, says former Utah Attorney General John Swallow.
-
3rd Circ. Clarifies Ch. 11 3rd-Party Liability Scope Post-Purdue
A recent Third Circuit decision that tort claims against the purchaser of a debtor's business belong to the debtor's bankruptcy estate reinvigorates the use of Chapter 11 for the resolution of nondebtor liability in mass tort bankruptcies following last year's U.S. Supreme Court ruling in Purdue Pharma, say attorneys at Sullivan & Cromwell.
-
Texas Suit Marks Renewed Focus On Service Kickback Theory
After a dormant period at the federal level, a theory of kickback enforcement surrounding nurse educator programs and patient support services resurfaced with a recent state court complaint filed by Texas against Eli Lilly, highlighting for drugmakers the ever-changing nature of enforcement priorities and industry landscapes, say attorneys at Sheppard Mullin.
-
Series
Power To The Paralegals: How And Why Training Must Evolve
Empowering paralegals through new models of education that emphasize digital fluency, interdisciplinary collaboration and human-centered lawyering could help solve workforce challenges and the justice gap — if firms, educators and policymakers get on board, say Kristine Custodio Suero and Kelli Radnothy.
-
Series
Playing Softball Makes Me A Better Lawyer
My time on the softball field has taught me lessons that also apply to success in legal work — on effective preparation, flexibility, communication and teamwork, says Sarah Abrams at Baleen Specialty.
-
5 Years In, COVID-19 Fraud Enforcement Landscape Is Shifting
As the government moves pandemic fraud enforcement from small-dollar individual prosecutions to high-value corporate cases, and billions of dollars remain unaccounted for, companies and defense attorneys must take steps now to prepare for the next five years of scrutiny, says attorney David Tarras.
-
Fed. Circ. In August: A Framework For AIA Derivation Disputes
In Global Health Solutions v. Selner, the Federal Circuit established how to assess derivation challenges under the America Invents Act's first-to-file system, making it easier for petitioners to determine a challenge's odds of success, say attorneys at Knobbe Martens.
-
USPTO's Track One A Reliable Patent Pathway Amid Backlog
As the U.S. Patent and Trademark Office faces a backlog of unexamined utility, plant and reissue patent applications, patent applicants should consider utilizing the USPTO's Track One Program, which not only expedites the process but also increases the likelihood of working with more senior examiners, says Ryan Schermerhorn at Marshall Gerstein.
-
Vanda Ruling Opens Door For Contesting FDA Drug Denials
The D.C. Circuit's recent decision in Vanda Pharmaceuticals v. U.S. Food and Drug Administration creates new opportunities and considerations for drug companies navigating the FDA approval process, establishing that litigation is an option when the FDA refuses to hold a hearing, say attorneys at Polsinelli.
-
Series
Law School's Missed Lessons: Mastering Time Management
Law students typically have weeks or months to prepare for any given deadline, but the unpredictability of practicing in the real world means that lawyers must become time-management pros, ready to adapt to scheduling conflicts and unexpected assignments at any given moment, says David Thomas at Honigman.
-
Rare Del. Oversight Ruling Sends Governance Wake-Up Call
An unusual ruling from the Delaware Court of Chancery recently allowed Caremark oversight claims to proceed against former executives of a company previously known as Teligent, sending a clear reminder that boards and officers must actively monitor and document oversight efforts when addressing mission-critical risks, say attorneys at WilmerHale.
-
How Hyperlinks Are Changing E-Discovery Responsibilities
A recent e-discovery dispute over hyperlinked data in Hubbard v. Crow shows how courts have increasingly broadened the definition of control to account for cloud-based evidence, and why organizations must rethink preservation practices to avoid spoliation risks, says Bree Murphy at Exterro.